Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 14, 2014 (13 years ago)

Fluoxetine Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Chemical Contamination: The recalling firm received notice that their supplier is recalling capsules due to complaints of capsules having an unusual odor.

Cause type: Chemical / undeclared

A chemical that should not be there - benzene, methanol, lead - or an undeclared prescription drug hidden in a supplement. The label gives no warning: you may be taking a toxic solvent, a heavy metal, or a drug such as sildenafil that interacts with your other medicines. All chemical / undeclared recalls.

What was recalled

Fluoxetine Capsules, USP, 20 mg, 30-count bottles, Rx only, Distributed by: Wal-Mart, Bentonville, AR 72716; Manufactured by: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960; Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045, NDC 68645-130-54, UPC 3 68645 13054 5.

Affected NDC 68645-0130-54

Compare with the code on your package — it is the most precise check available.

Drug: Fluoxetine Category: Mental Health Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Fluoxetine
NDC 68645-0130
HYDROCHLORIDE 20 mg/1 Capsule
Oral
Legacy Pharmaceutical Packaging, LLC Rx
Recalling firm
Legacy Pharmaceutical Packaging
NDC code
68645-130-54
Origin
MO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1279-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Fluoxetine recalls

See all
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0456-2025
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0455-2025
Class III · Low risk

Fluoxetine Tablets USP

Failed impurities/ degradation specifications: Teva Pharmaceuticals USA, Inc. is voluntarily recalling all lots within expiry due to out of specification (OOS) test result for the lactoside impurity obtained during routine stability testing activities.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7188-56 D-0578-2018
Class II · Moderate risk

Fluoxetine Capsules USP

Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the impurity.

Terminated Chemical / undeclared Teva Pharmaceuticals USA NDC 50111-648-02 D-0971-2015
Class II · Moderate risk

Fluoxetine Capsules USP

Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the impurity.

Terminated Chemical / undeclared Teva Pharmaceuticals USA NDC 50111-647-01 D-0970-2015

Other recalls by Legacy Pharmaceutical Packaging

All 2014 recalls
Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)

Ongoing Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1263-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.

Terminated Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1075-2019